Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model

BJU International

Volumn 105, Issue 10, 2010, Pages 1469-1476

  Jankun, Jerzy ^a,b   Selman, Steven H ^a   Keck, Rick W ^a   Łysiak Szydłowska, Wiesława ^b   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Experimental therapies; Haemostasis; Molecular biology; PAI 1 with very long half life

Indexed keywords

HEMOSTATIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; BLOOD COAGULATION; HEMORRHAGE; HEMOSTATICS; HUMANS; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 77951716697     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08962.x     Document Type: Article

References (57)

1. Cothren CC, Moore EE, Hedegaard HB, Meng K. Epidemiology of urban trauma deaths: a comprehensive reassessment 10 years later. World J Surg 2007 31 : 1507 1511
2. Holcomb JB. Methods for improved hemorrhage control. Crit Care 2004 8 (Suppl. 2 S57 60
3. Holcomb JB, McMullin NR, Pearse L et al. Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004. Ann Surg 2007 245 : 986 991
4. Sauaia A, Moore FA, Moore EE et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995 38 : 185 193
5. Urano T, Ihara H, Suzuki Y, Takada Y, Takada A. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity. Semin Thromb Hemost 2000 26 : 39 42
6. Gans H. Thrombogenic properties of epsilon amino caproic acid. Ann Surg 1966 163 : 175 178
7. Samojlova NA, Krayukhina MA, Yamskov IA. Use of the affinity chromatography principle in creating new thromboresistant materials. J Chromatogr B Analyt Technol Biomed Life Sci 2004 800 : 263 269
8. Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 2004 10 : 58 62
9. Dietrich W, Spannagl M, Boehm J et al. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Anesth Analg 2008 107 : 1469 1478
10. Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006 202 : 216 222
11. Ray MJ, Hales MM, Brown L, O'Brien MF, Stafford EG. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit. Ann Thorac Surg 2001 72 : 521 526
12. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008 358 : 771 783
13. Brohi K, Cohen MJ, Ganter MT et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008 64 : 1211 1217
14. Parsson H, Holmberg A, Siegbahn A, Bergqvist D. Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation. Eur J Vasc Endovasc Surg 2004 27 : 186 192
15. Valen G, Eriksson E, Risberg B, Vaage J. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994 8 : 324 330
16. Kuhli C, Luchtenberg M, Scharrer I, Hattenbach LO. Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefes Arch Clin Exp Ophthalmol 2005 243 : 963 966
17. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997 85 : 1258 1267
18. Pannekoek H, Veerman H, Lambers H et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986 5 : 2539 2544
19. Jankun J, Aleem AM, Selman SH et al. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med 2007 20 : 683 687
20. Jankun J, Aleem AM, Specht Z et al. PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med 2007 20 : 11 20
21. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008 14 : 1255 1260
22. Evans PA, Hawkins K, Lawrence M, Barrow MS, Williams PR, Williams RL. Studies of whole blood coagulation by oscillatory shear, thromboelastography and free oscillation rheometry. Clin Hemorheol Microcirc 2008 38 : 267 277
23. Gallimore MJ, Harris SL, Tappenden KA, Winter M, Jones DW. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 2005 3 : 2506 2513
24. Carroll RC, Craft RM, Chavez JJ, Snider CC, Kirby RK, Cohen E. Measurement of functional fibrinogen levels using the thrombelastograph. J Clin Anesth 2008 20 : 186 190
25. Carr ME Jr, Krishnamurti C, Alving BM. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis. Thromb Haemost 1992 67 : 106 110
26. Sugiki M, Maruyama M, Yoshida E, Mihara H, Kamiguti AS, Theakston DG. Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon 1995 33 : 1605 1617
27. Kohro S, Yamakage M, Omote T, Namiki A. In vitro effects of propofol on blood coagulability and fibrinolysis by the use of thromboelastograph technique. Acta Anaesthesiol Scand 1999 43 : 217 219
28. Haemoscope Corporation. TEG 5000 User's Manual Version 4. 2. Software.
29. Stein CS, Kang Y, Sauter SL et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 2001 3 : 850 856
30. Sukhotnik I, Krausz MM, Brod V et al. Divergent effects of oxygen therapy in four models of uncontrolled hemorrhagic shock. Shock 2002 18 : 277 284
31. Carmeliet P, Stassen JM, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993 92 : 2756 2760
32. Altman PL, Dittmer DS. Biological Data Book.
33. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003 2 : 19 28
34. Leigh JA, Hodgkinson SM, Lincoln RA. The interaction of Streptococcus dysgalactiae with plasmin and plasminogen. Vet Microbiol 1998 61 : 121 135
35. Ward PN, Abu-Median AB, Leigh JA. Structural consideration of the formation of the activation complex between the staphylokinase-like streptococcal plasminogen activator PadA and bovine plasminogen. J Mol Biol 2008 381 : 734 747
36. Feldman BF, Zinkl JG, Jain NC, Schalm OW, Weiss DJ. Schalm's Veterinary Hematology.
37. Barber CG, Dickinson RP. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl) guanidines. Bioorg Med Chem Lett 2002 12 : 185 187
38. Barber CG, Dickinson RP, Fish PV. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines. Bioorg Med Chem Lett 14 : 3227 3230
39. Katz BA, Mackman R, Luong C et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol 2000 7 : 299 312
40. Subasinghe NL, Travins JM, Ali F et al. A novel series of arylsulfonylthiophene- 2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett 2006 16 : 2200 2204
41. Smolarczyk K, Boncela J, Szymanski J, Gils A, Cierniewski CS. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis. Arterioscler Thromb Vasc Biol 2005 25 : 2679 2684
42. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 1992 267 : 17128 17135
43. Iishi H, Tatsuta M, Baba M, Yano H, Uehara H, Nakaizumi A. Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int J Cancer 1995 63 : 716 719
44. Racanelli AL, Diemer MJ, Dobies AC, Dubin JR, Reilly TM. Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model. Thromb Haemost 1992 67 : 692 696
45. Reilly CF, Fujita T, Mayer EJ, Siegfried ME. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler Thromb 1991 11 : 1276 1286
46. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and α-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007 5 : 812 817
47. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 2007 18 : 657 660
48. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007 12 : 2957 2966
49. Baynard T, Jacobs HM, Kessler CM, Kanaley JA, Fernhall B. Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training status. Eur J Appl Physiol 2007 101 : 595 602
50. Drinane MC, Sherman JA, Hall AE, Simons M, Mulligan-Kehoe MJ. Plasminogen and plasmin activity in patients with coronary artery disease. J Thromb Haemost 2006 4 : 1288 1295
51. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007 35 : 1821 1828
52. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Report 2001 8 : 463 470
53. Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH, Jankun J. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Report 1999 6 : 523 526
54. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL. Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci USA 2003 100 : 9168 9172
55. Wohl RC, Sinio L, Summaria L, Robbins KC. Comparative activation kinetics of mammalian plasminogens. Biochim Biophys Acta 1983 745 : 20 31
56. Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E. Accelerated thrombus lysis in blood of plasminogen activator inhibitor deficient mice is inhibited by very long half-life PAI-1. Pharmacol Rep 2009 61 : 673 680
57. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth 2004 93 : 842 858